The White House has threatened to slap tariffs on apparel and footwear, leading retailers to speak out about how this would hurt business.Retailread more
"We are now embarking on a new Long March, and we must start all over again!" Xi Jinping said.Marketsread more
CNBC's Jim Cramer says Morgan Stanley cutting its worst-case forecast on Tesla so drastically from $97 per share appears to be a gimmick.Investingread more
U.S. aviation officials believe a bird strike may have led to the deadly crash of an Ethiopian Airlines Boeing 737 Max in March, according to a person familiar with the...Aerospace & Defenseread more
The escalating trade war between China and the U.S. could increase pressure on the overall economy, according to Boston Fed President Eric Rosengren.The Fedread more
May outlined her new Brexit proposals which are being voted on by politicians next month.Europe Marketsread more
The Time's Up Legal Defense Fund, the American Civil Liberties Union and fast-food workers coalition Fight for $15 said Tuesday that they have filed 23 new complaints against...Restaurantsread more
Sales of existing U.S. homes fell 0.4% in April compared with March to a seasonally adjusted annualized rate of 5.19 million units, according to the National Association of...Real Estateread more
Japanese automakers say they generated more than 1.6 million jobs in the U.S. at manufacturing plants, dealerships and suppliers. Of those jobs, more than 94,000 people are...Autosread more
Morgan Stanley analysts said the reduction was driven by concerns around Chinese demand for Tesla products.Autosread more
The rigorous work schedule and pressure faced by U.S. doctors have them "stressed to the point of breaking" and struggling with the highest suicide rates among any profession...Healthy Returnsread more
Price is what you pay, but value, as Warren Buffett has observed, is what you get.
Lately, big-name investors like Bill Miller and Aswath Damodaran are betting they'll get more than they paid for out of shares of troubled Valeant Pharmaceuticals International, which on Monday named new leadership.
Both built positions in Valeant when it was trading around $32 a share, compared with its all-time closing high of $263 last August.
The company's deep and dramatic sell-off is a key part of their attraction. "It's probably the most toxic name in the market," Miller told CNBC's "Closing Bell " on Friday.
Valeant's share prices were up about 3 percent Monday, after the company named Joseph Papa to succeed Michael Pearson as chairman and chief executive. The company said Papa, the 60-year-old chairman and CEO of drug company Perrigo, is expected to join Valeant early next month.